Therapeutic potential of the original incretin hormone glucose-dependent insulinotropic polypeptide: diabetes, obesity, osteoporosis and Alzheimer's disease? (Q37779101)

From Wikidata

Jump to navigation Jump to search

scientific article published on September 2010

Language	Label	Description	Also known as
English	Therapeutic potential of the original incretin hormone glucose-dependent insulinotropic polypeptide: diabetes, obesity, osteoporosis and Alzheimer's disease?	scientific article published on September 2010

Statements

scholarly article

1 reference

Europe PubMed Central

23 August 2017

1 reference

Europe PubMed Central

Therapeutic potential of the original incretin hormone glucose-dependent insulinotropic polypeptide: diabetes, obesity, osteoporosis and Alzheimer's disease? (English)

1 reference

Europe PubMed Central

23 August 2017

Alzheimer's disease

0 references

0 references

0 references

0 references

author name string

Nigel Irwin

1

1 reference

Europe PubMed Central

23 August 2017

Victor Gault

2

1 reference

Europe PubMed Central

23 August 2017

Peter R Flatt

3

1 reference

Europe PubMed Central

23 August 2017

language of work or name

0 references

publication date

1 September 2010

1 reference

Europe PubMed Central

23 August 2017

Expert Opinion on Investigational Drugs

1 reference

Europe PubMed Central

23 August 2017

19

1 reference

Europe PubMed Central

23 August 2017

9

1 reference

Europe PubMed Central

23 August 2017

1039-1048

1 reference

Europe PubMed Central

23 August 2017

Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Biology of incretins: GLP-1 and GIP

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Glucose-dependent insulinotropic polypeptide (Gastric Inhibitory Polypeptide; GIP).

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Glucose-dependent insulinotropic peptide is an integrative hormone with osteotropic effects.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Glucose-dependent insulinotropic polypeptide is expressed in adult hippocampus and induces progenitor cell proliferation.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Evidence for beneficial effects of compromised gastric inhibitory polypeptide action in obesity-related diabetes and possible therapeutic implications.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Therapeutic potential for GIP receptor agonists and antagonists.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Glucose-dependent insulinotropic polypeptide activates the Raf-Mek1/2-ERK1/2 module via a cyclic AMP/cAMP-dependent protein kinase/Rap1-mediated pathway.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in beta(INS-1)-cells

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Glucose-dependent insulinotropic polypeptide (GIP): anti-diabetic and anti-obesity potential?

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Extrapancreatic effects of GIP and GLP-1.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

KATP channel closure ameliorates the impaired insulinotropic effect of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Antidiabetic potential of two novel fatty acid derivatised, N-terminally modified analogues of glucose-dependent insulinotropic polypeptide (GIP): N-AcGIP(LysPAL16) and N-AcGIP(LysPAL37).

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Degradation, insulin secretion, and antihyperglycemic actions of two palmitate-derivitized N-terminal pyroglutamyl analogues of glucose-dependent insulinotropic polypeptide.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

GIP(Lys16PAL) and GIP(Lys37PAL): novel long-acting acylated analogues of glucose-dependent insulinotropic polypeptide with improved antidiabetic potential.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

A novel, long-acting agonist of glucose-dependent insulinotropic polypeptide suitable for once-daily administration in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Evaluation of the antidiabetic activity of DPP IV resistant N-terminally modified versus mid-chain acylated analogues of glucose-dependent insulinotropic polypeptide.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Fatty acid derivatised analogues of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

C-terminal mini-PEGylation of glucose-dependent insulinotropic polypeptide exhibits metabolic stability and improved glucose homeostasis in dietary-induced diabetes

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Prolonged GIP receptor activation using stable mini-PEGylated GIP improves glucose homeostasis and beta-cell function in age-related glucose intolerance

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Contribution of site-specific PEGylation to the dipeptidyl peptidase IV stability of glucose-dependent insulinotropic polypeptide

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Molecular mechanisms underlying nutrient-stimulated incretin secretion

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like Peptide-1 and glucose-dependent insulinotropic Peptide release

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Nutrient-dependent secretion of glucose-dependent insulinotropic polypeptide from primary murine K cells

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Molecular mechanisms underlying nutrient detection by incretin-secreting cells

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Activation of sodium-glucose cotransporter 1 ameliorates hyperglycemia by mediating incretin secretion in mice

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Glucose-dependent insulinotropic peptide stimulates proliferation and TGF-beta release from MG-63 cells.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Gastric inhibitory polypeptide as an endogenous factor promoting new bone formation after food ingestion

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Impact of glucose-dependent insulinotropic peptide on age-induced bone loss

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Gastric inhibitory polypeptide (GIP) binding sites in rat brain.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Immunohistochemical distribution of glucose-dependent insulinotropic polypeptide in the adult rat brain

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Effects of glucose-dependent insulinotropic peptide on behavior

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Protease-resistant glucose-dependent insulinotropic polypeptide agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

GIP biology and fat metabolism

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Abnormalities of GIP in spontaneous syndromes of obesity and diabetes in mice

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Orlistat accelerates gastric emptying and attenuates GIP release in healthy subjects.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Inhibition of gastric inhibitory polypeptide signaling prevents obesity

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Characterization of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent insulinotropic polypeptide

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro3)GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Vaccination against GIP for the treatment of obesity

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Active immunisation against gastric inhibitory polypeptide (GIP) improves blood glucose control in an animal model of obesity-diabetes

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Targeted ablation of glucose-dependent insulinotropic polypeptide-producing cells in transgenic mice reduces obesity and insulin resistance induced by a high fat diet

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

RS4-type resistant starch prevents high-fat diet-induced obesity via increased hepatic fatty acid oxidation and decreased postprandial GIP in C57BL/6J mice

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Similar incretin secretion in obese and non-obese Japanese subjects with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Identifiers

10.1517/13543784.2010.513381

1 reference

Europe PubMed Central

23 August 2017

1 reference

Europe PubMed Central

23 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37779101&oldid=2090679418"